Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

Published: 2026-04-22 07:23:21 ET BSX

Published on 04/22/2026 at 07:23 am EDT

By Rob Curran

Boston Scientific said its first-quarter net income roughly doubled as demand continued to grow worldwide for its stents, catheters and other cardiology devices, but the company cut its adjusted earnings growth projection for the year.

The Marlborough, Mass., medical-device maker posted first-quarter earnings of $1.34 billion, or 90 cents a share, up from $674 million, or 45 cents a share, a year earlier.

Excluding certain one-off items, the company logged first-quarter adjusted earnings of 80 cents a share, edging the average Wall Street target of 79 cents a share, as provided by FactSet.

Sales rose 12% to $5.2 billion, topping the mean analyst estimate of $5.17 billion, as per FactSet. Sales of cardiology devices rose 14% to $3.5 billion, while sales at its MedSurg surgery equipment unit rose 7.8% to $1.7 billion. Sales grew in all regions, with the Latin America and Canada region seeing a 19% increase.

For the second quarter, the stent maker forecast adjusted earnings in a range between 82 cents and 84 cents a share on sales growth of 5.5% to 7.5%. On an organic basis, excluding certain skew factors such as foreign exchange, the company targeted sales growth between 5% and 7%.

Boston Scientific cut its projection for 2026 adjusted earnings to a range between $3.34 and $3.41 a share from a prior estimated range between $3.43 and $3.49 a share. Analysts targeted adjusted earnings of $3.45 a share for the year.

For 2026, the company projects sales growth in a range between 7% and 8.5%, which translates to $21.78 billion at the high end, based on 2025 sales of $20.07 billion. On average, analysts anticipate sales of $22.24 billion for 2026. Boston Scientific expects sales to grow 6.5%-to-8% on an organic basis.

In February, it had targeted sales growth for the year between 10.5% and 11.5%, or between 10% to 11% on an organic basis.

Write to Rob Curran at [email protected]

(END) Dow Jones Newswires

04-22-26 0722ET